Pennsylvania is currently home to 3311 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Rehab CARES In USA: Clinical Trial
NCT05542121
Recruiting
In Phase 2, Patients in a community-based setting who have had a stroke will be evaluated by rehabilitation professionals and asked to perform a battery of clinical assessments before and after standard of care and robot assisted therapy with Rehab CARES system of simple force-feedback robots that are adapted to deliver single and group therapy.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/27/2024
Locations: Mercy Living Independently for Elders (L.I.F.E) - West Philadelphia, Philadelphia, Pennsylvania
Conditions: Stroke, Hemiplegia
Register for Updates
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: Sarah Cannon, SCRI Oncology Partners, Sidney Kimmel Cancer Center - Thomas Jefferson Hospital, Philadelphia, Pennsylvania
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Register for Updates
Optimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children
NCT05703347
Recruiting
The overall objective of this application is to develop a mobile health platform for the pediatric care setting to promote longer sleep duration for childhood obesity prevention.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/26/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Insufficient Sleep, Obesity
Register for Updates
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
NCT05616793
Recruiting
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/26/2024
Locations: University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: LCA5
Register for Updates
Ubuntu - I Am Because We Are
NCT05314179
Recruiting
The program will provide Advocacy and Support for Black patients with advanced-stage cancer in the Pittsburgh area. The goals are to: 1) provide a community-based, trained companion to journey alongside the patient with advanced cancer, 2) to help the individual explore meaning and create legacy, 3); offer support and navigation for practical needs of illness (e.g., financial assistance for food and housing, accessing and affording medications, transportation); and 4) to provide support and conn... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Metastatic Cancer
Register for Updates
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
NCT03053193
Recruiting
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2024
Locations: St. Luke's Hospital, Bethlehem, Pennsylvania
Conditions: Breast Cancer
Register for Updates
Community Resiliency Collective Efficacy Intervention
NCT05768217
Recruiting
This study will evaluate, via a cluster-randomized controlled trial, the effectiveness of a community-centered intervention that promotes thriving and resiliency to reduce community violence.
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/25/2024
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Social Cohesion, Violence, Physical, Violence, Non-accidental, Violence, Sexual, Violence, Domestic, Violence, Structural, Violence in Adolescence, Community Violence
Register for Updates
Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer
NCT05540899
Recruiting
This phase I trial is looking to determine if hypofractionated radiation therapy can be given safely after surgery for intermediate-risk head and neck cancer.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/25/2024
Locations: Milton S. Hershey Medical Center, Hershey, Pennsylvania
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Oral Cavity
Register for Updates
Detection of Prostate Cancer Using Voided Urine
NCT04788277
Recruiting
This study collects urine from male patients seen at the urology clinic to detect prostate cancer cells, shed in voided urine, using the optical imaging method developed in the laboratory, which targets certain biomarkers expressed on prostate cancer cells. The information learned from this study may allow researchers develop a simple diagnostic test for the management of those patients who have elevated prostate specific antigen (PSA) and are suspected to have prostate cancer. It may also help... Read More
Gender:
MALE
Ages:
Between 50 years and 79 years
Trial Updated:
06/25/2024
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Prostate Carcinoma
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
NCT04514653
Recruiting
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for tre... Read More
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
06/25/2024
Locations: Philadelphia Location, Philadelphia, Pennsylvania
Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Register for Updates
Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
NCT06355895
Recruiting
Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2024
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Upper Abdominal Malignancies
Register for Updates
taVNS for FRNS in Children
NCT05588063
Recruiting
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated non invasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated... Read More
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
06/24/2024
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Register for Updates